A new type of ERK1/2 autophosphorylation causes cardiac hypertrophy

被引：0
|
作者：
Kristina Lorenz
Joachim P Schmitt
Eva M Schmitteckert
Martin J Lohse
机构：
[1] Institute of Pharmacology and Toxicology,
[2] University of Würzburg,undefined
[3] Versbacher Straße 9,undefined
[4] Rudolf Virchow Center,undefined
[5] DFG Research Center for Experimental Biomedicine,undefined
[6] University of Würzburg,undefined
[7] Versbacher Straße 9,undefined
来源：
Nature Medicine | 2009年 / 15卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Mitogen-activated protein (MAP) kinases are known to promote cardiac hypertrophy, but how upstream hypertrophic signals induce these kinases to cause hypertrophy has not been clear. Lorenz et al. now uncover a new mechanism of MAP kinase activation and demonstrate the crucial role that this mechanism has in the hypertrophic response.
引用
收藏
页码：75 / 83
页数：8
相关论文
共 50 条
  • [1] A new type of ERK1/2 autophosphorylation causes cardiac hypertrophy
    Lorenz, Kristina
    Schmitt, Joachim P.
    Schmitteckert, Eva M.
    Lohse, Martin J.
    NATURE MEDICINE, 2009, 15 (01) : 75 - 83
  • [2] CREG, a new regulator of ERK1/2 in cardiac hypertrophy
    Xu, L
    Liu, JM
    Chen, LY
    JOURNAL OF HYPERTENSION, 2004, 22 (08) : 1579 - 1587
  • [3] The dimer interface of ERK1/2 provides an alternative targeting strategy to interfere with ERK1/2 mediated cardiac hypertrophy
    Tomasovic, A.
    Huemmert, M.
    Kramer, S.
    Gruse, T.
    Katus, H. A.
    Lohse, M. J.
    Mueller, O.
    Lorenz, K.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2016, 389 (01) : S4 - S5
  • [4] A new potential strategy for targeting pathological cardiac hypertrophy: the dimer interface of ERK1/2
    Tomasovic, A.
    Huemmert, M.
    Lorenz, K. Kristina
    EUROPEAN JOURNAL OF HEART FAILURE, 2016, 18 : 432 - 432
  • [5] Monomeric ERK2 attenuates ERK1/2-mediated pathological cardiac hypertrophy
    Tomasovic, Angela
    Huemmert, Martin
    Ruppert, Catharina
    Lohse, Martin J.
    Lorenz, Kristina
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2014, 387 : S20 - S20
  • [6] Inhibition of ERK dimerization prevents the development of ERK1/2-mediated cardiac hypertrophy
    Huemmert, M.
    Vidal, M.
    Schmitt, J. P.
    Lohse, M. J.
    Lorenz, K.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2011, 383 : 26 - 26
  • [7] Cardiac hypertrophy: Targeting Raf/MEK/ERK1/2-signaling
    Lorenz, Kristina
    Schmitt, Joachim P.
    Vidal, Marie
    Lohse, Martin J.
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2009, 41 (12): : 2351 - 2355
  • [8] Extracellular signal-regulated kinase 1/2 (ERK1/2) signaling in cardiac hypertrophy
    Kehat, Izhak
    Molkentin, Jeffery D.
    ANALYSIS OF CARDIAC DEVELOPMENT: FROM EMBRYO TO OLD AGE, 2010, 1188 : 96 - 102
  • [9] Selective interference with nuclear ERK1/2 signaling prevents pathological cardiac hypertrophy
    Ruppert, C.
    Vidal, M.
    Lohse, M. J.
    Lorenz, K.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2013, 386 : S68 - S68
  • [10] SPECIFIC INTERFERENCE WITH NUCLEAR ERK1/2 SIGNALING PREVENTS PATHOLOGICAL CARDIAC HYPERTROPHY
    Ruppert, C.
    Deiss, K.
    Herrmann, S.
    Vidal, M.
    Oezkur, M.
    Gorski, A.
    Weidemann, F.
    Lohse, M. J.
    Lorenz, K.
    CARDIOLOGY, 2013, 126 : 17 - 17
12345